3月4日晚间,港股创新药公司康宁杰瑞(09966.HK)发布业绩预盈公告。公司预计2024年度利润不少于1.5亿元,而截至2023年度则亏损约2.1亿元。本次为公司首次实现年度盈利。康宁杰瑞称,公司于报告期内转亏为盈,主要基于三项授权合作和销售收入。康宁杰瑞曾于2024年1月、6月和9月先后与三家公司达成商业协议,获得预付款收入。其中,9月份交易的4亿元预付款成为扭亏的关键。2024年9月,康宁...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.